Biologic May Tame Severe Asthma

March 5, 2014 4:31 PM

20 0

SAN DIEGO -- Lebrikizumab, a novel monoclonal antibody against the inflammatory cytokine IL-13, might have reduced exacerbations in severe asthma in a randomized trial, although manufacturing problems undermined any conclusions.

Overall, the monthly injections cut asthma exacerbations a relative 36% compared with placebo (0.68 versus 0.43 per year), Nicola Hanania, MD, of Baylor College of Medicine in Houston, showed in combined analysis of the LUTE and VERSE trials.

Read more

To category page